There is no cost to attend the Summit, but advanced registration is required. Self-pay options for meals, if required by your employer, will be offered on-site.
Melissa Antman, PhD
Senior Scientific Program Analyst, Center for Research Strategy (CRS), National Cancer Institute
Dr. Antman is a Senior Scientific Program Analyst in the Center for Research Strategy (CRS) at the National Cancer Institute, where she leads portfolio analysis activities and makes recommendations for policies and decisions based on analyses. She came to the NIH in 2007 as an American Association for the Advancement of Science (AAAS) Science and Technology Policy Fellow at the National Heart, Lung, and Blood Institute, and she worked there following her fellowship until she came to CRS in 2015. Prior to the NIH, Dr. Antman worked in research and development in the pharmaceutical industry as an investigator in pharmaceutics. She holds a A.B. in Chemistry from Dartmouth College and a Ph.D. in Chemistry from the University of Wisconsin.
L. Michelle Bennett, PhD
Director, Center for Research Strategy National Cancer Institute
Dr. Bennett directs the Center for Research Strategy, a science-based office that since 2015 collaboratively develops recommendations for addressing scientific opportunities, monitors the direction and application of the NCI’s scientific knowledge and resources, and identifies research funding gaps. Prior to taking on this role, she served as the deputy scientific director of the Division of Intramural Research at the National Heart, Lung, and Blood Institute and before that was deputy director at NCI’s Center for Cancer Research. Dr. Bennett earned her Ph.D. in oncology from the University of Wisconsin–Madison studying genetic susceptibility to cancer and, as a postdoctoral fellow at the National Institute of Environmental Health Sciences, performed some of the earliest work on BRCA1 and BRCA2 including the characterization and localization of BRCA1 to the long arm of Chromosome 17.
Dr. Bennett has extensive practical experience in promoting collaboration and team-based approaches by bringing together research scientists with diverse backgrounds and expertise to solve complex scientific problems. She has supported efforts to increase diversity in the biomedical workforce, played a leadership role in launching and building the NIH Stadtman Tenure Track Investigator program, and developed a trans-NIH web presence for the NIH Intramural program. Dr. Bennett is the recipient of many awards, including NIH and Institute Director’s Awards, the NCI Women’s Scientist Advisors Achievement Award, and the NCI Exceptional Mentor Award.
John P.A. Loannidis, MD, DSc
Professor and Co-Director, Meta-Research Innovation Center, Stanford University
John P.A. Ioannidis holds the C.F. Rehnborg Chair in Disease Prevention at Stanford University, where he is Professor of Medicine, Professor of Health Research and Policy, and Professor (by courtesy) of Biomedical Data Science at the School of Medicine, Professor (by courtesy) of Statistics at the School of Humanities and Sciences, co-Director of the Meta-Research Innovation Center at Stanford, and Director of the PhD program in Epidemiology and Clinical Research. He has delivered ~500 invited and honorary lectures and he is the recipient of many awards (e.g. European Award for Excellence in Clinical Science , Medal for Distinguished Service, Teachers College, Columbia University , Chanchlani Global Health Award , Epiphany Science Courage Award ). He has been inducted in the Association of American Physicians (2009), the European Academy of Cancer Sciences (2010), the American Epidemiological Society (2015), and the European Academy of Sciences and Arts (2015) and has served as President of the Society for Research Synthesis Methodology. He has received honorary titles from FORTH (2014) and Ioannina (2015), honorary doctorates from Erasmus U Rotterdam (2015) and U Athens (2017) and multiple honorary lectureships/visiting professorships (Caltech, Oxford, LSHTM, Yale, U Utah, U Conn, UC Davis, U Penn among others). The PLoS Medicine paper on “Why most published research findings are false” has been the most-accessed article in the history of Public Library of Science (with >2.5 million hits to-date) and has generated new directions for assessing scientific efficiency, reliability, and reproducibility. He is a Highly Cited Researcher according to Clarivate Analytics in both Clinical Medicine and in Social Sciences and among the 10 scientists with the highest current citation rate in the world (currently over 3,000 new citations are made to his work each month in the scientific literature according to Google Scholar). His work has been influential across multiple scientific disciplines. He has pioneered the field of meta-research, using sophisticated methods to study science itself and the way research practices can be optimized to make scientific investigation more rigorous and more efficient, diminishing biases and promoting integrity.
Richard Klavans, PhD
Founder and Chairman, SciTech Strategies
Dick Klavans has published extensively on the art and science of science mapping. He has created these maps of science for research planning in industry (Abbott Labs, Astra Zeneca, DuPont, Glaxo, Kellogg, Kraft, SmithKline Beecham and Unilever), government agencies (DOE, NSF, NIH and IARPA) and over 20 universities. His most publications show how one can predict funding patterns at an extremely detailed level (funding predictions for over 90,000 topics) and proposal success (from the perspective of those submitting research grants).
Hannah Valantine, MD, MRCP, FACC
NIH Chief Officer for Scientific Workforce Diversity
Hannah Valantine is the first NIH Chief Officer for Scientific Workforce Diversity, and a Senior Investigator in the Intramural Research Program at the National Heart, Lung, and Blood Institute. Prior to starting this position in April 2014, Dr. Valantine was Professor of Cardiovascular Medicine and the Senior Associate Dean for Diversity and Leadership at Stanford, a leadership position she held since November 2004. She is nationally recognized for her transformative approaches to diversity and is a recipient of the NIH Director’s Pathfinder Award for Diversity in the Scientific Workforce. She is currently leading NIH efforts to promote diversity through innovation across the NIH-funded biomedical workforce through a range of evidence-based approaches. Dr. Valantine maintains an active clinical research program that continues to have high impact on patient care. Current research extends her previous finding that an organ transplant is essentially a genome transplant, and that monitoring the level of donor DNA in a recipient’s blood as a marker of organ damage will detect early stages of rejection. She is currently overseeing a multi-site consortium of mid-Atlantic transplant centers to validate these findings clinically toward the development of a non-invasive tool for detecting early signs of organ rejection.